How to balance the urgency to treat AML and the wait for molecular testing results?

IVO Bridge – Episode 1
In this video, Dr. Eytan Stein presents the decision-making process for balancing the urgency of treating AML with waiting for molecular testing results, highlighting findings from the Beat AML (BAML) study that suggest waiting for targeted therapy assignments does not negatively impact patient survival compared to starting standard therapy immediately.

Dr. Eytan Stein – Hematologist – Oncologist – Memorial Sloan Kettering Cancer Center, New York, USA